Why the study?
Does ONO-1101 demonstrate greater beta-blocking activity and cardioselectivity compared to esmolol in preclinical models?
Population
In vivo and in vitro preclinical models
Comparison
ONO-1101 (ultra short-acting beta-blocker) vs Esmolol
Design
Preclinical
Authors
Loading...
Supports preclinical development of novel ultra-short-acting beta-blockers; leaves open clinical translation pending human trials.
Does ONO-1101 demonstrate greater beta-blocking activity and cardioselectivity compared to esmolol in preclinical models?
ONO-1101 is a novel, highly cardioselective ultra short-acting beta-blocker that demonstrates greater potency and selectivity than esmolol in preclinical models.
Iguchi et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: